Last reviewed · How we verify

FF/VI (100/25) mcg — Competitive Intelligence Brief

FF/VI (100/25) mcg (FF/VI (100/25) mcg) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inhaled corticosteroid/long-acting beta-2 agonist combination. Area: Respiratory/Pulmonology.

phase 3 Inhaled corticosteroid/long-acting beta-2 agonist combination Glucocorticoid receptor (fluticasone furoate); Beta-2 adrenergic receptor (vilanterol) Respiratory/Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

FF/VI (100/25) mcg (FF/VI (100/25) mcg) — GlaxoSmithKline. FF/VI is a combination of fluticasone furoate (inhaled corticosteroid) and vilanterol (long-acting beta-2 agonist) that reduces airway inflammation and improves bronchodilation in respiratory disease.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
FF/VI (100/25) mcg TARGET FF/VI (100/25) mcg GlaxoSmithKline phase 3 Inhaled corticosteroid/long-acting beta-2 agonist combination Glucocorticoid receptor (fluticasone furoate); Beta-2 adrenergic receptor (vilanterol)
Symbicort Turbuhaler 160/4.5 Symbicort Turbuhaler 160/4.5 AstraZeneca marketed Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA) Glucocorticoid receptor (budesonide); beta-2 adrenergic receptor (formoterol)
CHF1535 CHF1535 Chiesi Farmaceutici S.p.A. marketed Inhaled corticosteroid/long-acting beta-2 agonist combination Glucocorticoid receptor; beta-2 adrenergic receptor
Fluticasone/Salmeterol HFA Fluticasone/Salmeterol HFA GlaxoSmithKline marketed Inhaled corticosteroid/long-acting beta-2 agonist combination Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol)
fluticasone/salmeterol fluticasone/salmeterol Hull University Teaching Hospitals NHS Trust marketed Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA) Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol)
FLIXOTIDE and SERETIDE FLIXOTIDE and SERETIDE GlaxoSmithKline marketed Inhaled corticosteroid (FLIXOTIDE); Inhaled corticosteroid/long-acting beta-2 agonist combination (SERETIDE) Glucocorticoid receptor (fluticasone); Beta-2 adrenergic receptor (salmeterol)
RELVAR/BREO RELVAR/BREO GlaxoSmithKline marketed Inhaled corticosteroid/long-acting beta-2 agonist combination Glucocorticoid receptor; beta-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inhaled corticosteroid/long-acting beta-2 agonist combination class)

  1. GlaxoSmithKline · 14 drugs in this class
  2. Pearl Therapeutics, Inc. · 5 drugs in this class
  3. AstraZeneca · 4 drugs in this class
  4. Research in Real-Life Ltd · 3 drugs in this class
  5. Chiesi Farmaceutici S.p.A. · 2 drugs in this class
  6. Istituto per la Ricerca e l'Innovazione Biomedica · 1 drug in this class
  7. Johns Hopkins University · 1 drug in this class
  8. National Jewish Health · 1 drug in this class
  9. SkyePharma AG · 1 drug in this class
  10. University Medical Center Groningen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). FF/VI (100/25) mcg — Competitive Intelligence Brief. https://druglandscape.com/ci/ff-vi-100-25-mcg. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: